Mutations and/or deletions of the tumor-suppressor gene TP53 (located on the short arm of chromosome 17) occur in 2–20%, are more common in older patients and patients with secondary or therapy-related AML, and are associated with complex cytogenetics38–41. The gene discussed is TP53; the disease is acute myeloid leukemia.